Science Pool

Evotec receives € 7.5 m grant for development of COVID-19 therapeutic

Evotec SE announced today that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID 19. Evotec is one of three companies receiving a highly competitive grant as part of a new initiative by the BMBF to support the clinical development of novel therapeutic candidates against COVID-19.

Read More

Twitter
LinkedIn
Email
Generated by Feedzy